Paul Brennan, MSC, BSC

Paul Brennan has over 30 years of experience in the pharmaceutical and biotech industries working in leadership roles in general management, corporate strategy, commercial planning, business development and regulatory affairs in Canada, Sweden, the UK, and the USA. Most recently Mr. Brennan’s experiences include senior business development and management positions in various biotech companies, including Aquinox, Arbutus Biopharma, Aspreva, and AnorMED. Mr. Brennan has a comprehensive list of business development and licensing transactions, totalling over $3 billion in value: he played key roles in the merger of Tekmira and OnCore to create Arbutus, in the sale of Aspreva to Vifor for $915 million and in the sale of AnorMED to Genzyme for $580 million. Prior to working in biotech, Mr. Brennan held senior roles in Business Development and Regulatory Affairs at AstraZeneca. Mr. Brennan holds a MSc in Physiology, and a BSc (Hons) in Life Sciences from Queen’s University in Kingston, ON.